Vivo Bio Tech Ltd. Unveils New 15,000 Sq. Ft. Large Animal Facility! | MCap 75.53 Cr | PE 9.86

📈 Exciting expansion! Vivo Bio Tech Ltd. has launched a state-of-the-art facility for large animal studies, enhancing their research capabilities! 🐾

🔑 Key Highlights:

- Vivo Bio Tech Ltd. has launched a new large animal facility.
- The facility spans 15,000 sq. ft. and is approved by CPCSEA.
- Funding came from both internal accruals and institutional debt.
- The facility will house and conduct studies on canines, pigs, mini-pigs, sheep, and goats.
- Operations have already commenced, offering services like Pharmacokinetic (PK), Pharmacodynamic (PD), Surgical Studies, and Toxicology Studies.
- Supports an expanding list of major pharmaceutical and bio-pharmaceutical companies.
- Enhances existing services including In-vitro and In-vivo Small Animal Studies and Eco-Toxicology.
- Aims to provide comprehensive Investigational New Drug (IND) packages to global clients.
- Joins a select group of Contract Research Organizations (CROs) equipped for both large and small animal research.

🔹Company Profile:

Name: VIVO BIO TECH LTD
Symbol: VIVOBIOT, BSE:511509
PE: 9.86
Market Cap: ₹75.53 Cr. == Approx. $0.01 B
Sector: Healthcare - Biotechnology

💬 What do you think about this new development? Share your thoughts in the comments!

Follow us for more realtime updates!

🕒 This update of VIVO BIO TECH LTD was recorded at January 13, 2025, 10:11 AM

Disc: Information provided in this tweet can be inaccurate, verify through the source before making any investment decision.